Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed COO
STEMLINE THERAPEUTICS INC (STML) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/10/2020 8-K Resignation/termination of a director
Docs: "Amended and Restated Certificate of Incorporation of Stemline Therapeutics, Inc.",
"Amended and Restated By-Laws of Stemline Therapeutics, Inc."
05/04/2020 8-K Quarterly results
03/13/2020 8-K Quarterly results
11/07/2019 8-K Quarterly results
08/09/2019 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Underwriting Agreement, between Stemline Therapeutics, Inc. and J.P. Morgan Securities LLC, as representative of the several underwriters named therein",
"Opinion of Alston & Bird LLP"
08/02/2019 8-K Quarterly results
Docs: "Stemline Therapeutics Reports Second Quarter 2019 Financial Results"
06/28/2019 8-K Quarterly results
05/10/2019 8-K Quarterly results
Docs: "Stemline Therapeutics Reports First Quarter 2019 Financial Results"
04/29/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "Press release issued by Stemline Therapeutics, Inc., announcing New England Journal of Medicine Publication of ELZONRIS (tagraxofusp) Pivotal Study Results"
03/15/2019 8-K Quarterly results
Docs: "Stemline Therapeutics Reports Fourth Quarter 2018 Financial Results NEW YORK, Mar. 15, 2019 — Stemline Therapeutics, Inc. , a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today financial results for the quarter ended December 31, 2018. The Company also reviewed recent milestones: ELZONRIS™ — US Approval and Commercial Launch"
01/16/2019 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Underwriting Agreement, between Stemline Therapeutics, Inc. and J.P. Morgan Securities LLC, as representative of the several underwriters named therein",
"Opinion of Alston & Bird LLP"
12/21/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "FDA Approves ELZONRISTM , the First Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm and First CD123-Targeted Therapy"
11/08/2018 8-K Quarterly results
Docs: "Stemline Therapeutics Reports Third Quarter 2018 Financial Results NEW YORK, November 8, 2018 — Stemline Therapeutics, Inc. , a biopharmaceutical company focused on the development and potential commercialization of novel oncology therapeutics, announced today financial results for the quarter ended September 30, 2018. The Company also reviewed recent clinical and regulatory events, and outlined key upcoming milestones: ELZONRIS — Potential Approval and Pre-Commercial Activities"
08/13/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Stemline Therapeutics Announces that FDA Accepts ELZONRISTM Biologics License Application and Grants Priority Review · Conference call on BLA acceptance and commercial readiness scheduled for Monday, August 13, 2018 at 8:30 AM ET"
08/09/2018 8-K Quarterly results
Docs: "Stemline Therapeutics Reports Second Quarter 2018 Financial Results"
06/26/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Stemline Therapeutics Announces Completion of Rolling BLA Submission for ELZONRIS™ for the Treatment of BPDCN"
06/22/2018 8-K Submission of Matters to a Vote of Security Holders
05/10/2018 8-K Quarterly results
Docs: "Stemline Therapeutics Reports First Quarter 2018 Financial Results NEW YORK, May 9, 2018 — Stemline Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today financial results for the quarter ended March 31, 2018. The Company also reviewed recent clinical and regulatory events, and outlined key upcoming milestones: SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm"
04/17/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/16/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Distribution Agreement, between Stemline Therapeutics, Inc., J.P. Morgan Securities LLC, Cantor Fitzgerald & Co. and Ladenburg Thalmann & Co. Inc",
"Opinion of Alston & Bird LLP"
03/16/2018 8-K Quarterly results
Docs: "Stemline Therapeutics Reports Fourth Quarter 2017 Financial Results"
01/24/2018 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Underwriting Agreement, between Stemline Therapeutics, Inc. and J.P. Morgan Securities LLC and Cowen and Company, LLC, as representatives of the several underwriters named therein",
"Opinion of Alston & Bird LLP"
12/13/2017 8-K Other Events, Financial Statements and Exhibits
Docs: "Stemline Therapeutics Presents Detailed SL-401 Pivotal Data in BPDCN at ASH and Kicks Off its BPDCN Awareness Campaign; Updated Results From Ongoing Trials in Additional Malignancies Also Presented , December 13, 2017 —Stemline Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, presented detailed data from its SL-401 pivotal trial in BPDCN, as well as results from other ongoing trials in additional indications, at the 2017 American Society of Hematology Annual Meeting and Exposition, held in Atlanta, GA. Presentations are available on the Stemline website, www.stemline.com, under the Scientific Presentations tab. SL-401: Pivotal Trial in BPDCN — Primary endpoint met; Median overall survival not reached in first-line...",
"2017 ASH Conference Presentation in use beginning December 9, 2017 (furnished only)"
11/09/2017 8-K Quarterly results
Docs: "Stemline Therapeutics Reports Third Quarter 2017 Financial Results , November 9, 2017 —Stemline Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced today financial results for the quarter ended September 30, 2017. The Company also reviewed recent clinical and regulatory events, and outlined key upcoming milestones: Pivotal Trial of SL-401 In Blastic Plasmacytoid Dendritic Cell Neoplasm"
11/01/2017 8-K Quarterly results
08/08/2017 8-K Quarterly results
Docs: "Stemline Therapeutics Reports Second Quarter 2017 Financial Results , August 8, 2017 —Stemline Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced today financial results for the quarter ended June 30, 2017. The Company also reviewed recent clinical and regulatory events, and outlined key upcoming milestones: SL-401 In Blastic Plasmacytoid Dendritic Cell Neoplasm"
06/20/2017 8-K Form 8-K - Current report
05/10/2017 8-K Form 8-K - Current report
03/24/2017 8-K Form 8-K - Current report
03/17/2017 8-K Form 8-K - Current report
01/20/2017 8-K Form 8-K - Current report
01/06/2017 8-K Form 8-K - Current report
11/08/2016 8-K Quarterly results
Docs: "Stemline Therapeutics Reports Third Quarter 2016 Financial Results and Highlights Recent Regulatory and Clinical Progress"
08/25/2016 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy